BRIEF-Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027

AIM ImmunoTech Inc. Common Stock

AIM ImmunoTech Inc. Common Stock

AIM

0.00

June 18 (Reuters) - AIM ImmunoTech Inc AIM.A:

  • AIM IMMUNOTECH - DURIPANC PRIMARY ENDPOINT ANALYSIS TO BEGIN DECEMBER 2026; TOPLINE RESULTS EXPECTED Q1 2027

  • AIM IMMUNOTECH - DURIPANC SECONDARY ENDPOINT ANALYSIS EXPECTED TO BEGIN JUNE 2027

Source text: ID:nGNX4ZcQ9T

Further company coverage: AIM.A


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.